Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Placebo 40 or 80 mg

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,152 result(s) found for: Placebo 40 or 80 mg. Displaying page 12 of 58.
    «« First « Previous 8  9  10  11  12  13  14  15  16  Next» Last»»
    EudraCT Number: 2016-000641-31 Sponsor Protocol Number: M14-234 Start Date*: 2016-09-20
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10009900 Colitis ulcerative PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) NL (Completed) FI (Completed) HU (Completed) CZ (Completed) SE (Completed) PL (Completed) IE (Completed) PT (Completed) DE (Completed) LV (Completed) LT (Completed) AT (Completed) GR (Completed) BE (Completed) EE (Completed) NO (Completed) ES (Completed) GB (GB - no longer in EU/EEA) FR (Completed) HR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2021-005092-39 Sponsor Protocol Number: TA-8995-304 Start Date*: 2022-08-25
    Sponsor Name:NewAmsterdam Pharma BV
    Full Title: Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular...
    Medical condition: atherosclerotic cardiovascular disease (ASCVD)
    Disease: Version SOC Term Classification Code Term Level
    26.0 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 100000004866 10076622 Atherosclerotic plaque LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) SK (Trial now transitioned) NL (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned) DK (Trial now transitioned) CZ (Trial now transitioned) FI (Trial now transitioned) LV (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000015-10 Sponsor Protocol Number: KL4-BPD-01 Start Date*: 2005-07-29
    Sponsor Name:Discovery Laboratoryies, INC
    Full Title: A Randomized, Double-blind, Placebo-Controlled Trial to Assess the Safety and Efficacy of Surfaxinâ (lucinactant), in Very Low Birth Weight (VLBW) Infants at Risk for Developing Bronchopulmonary Dy...
    Medical condition: In VLBW premature infants who have been intubated and received surfactants for the prevention or treatment of respiratory distress syndrome (RDS)
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003819-31 Sponsor Protocol Number: D1050229 Start Date*: 2008-04-02
    Sponsor Name:Dainippon Sumitomo Pharma America, Inc
    Full Title: A Phase 3 Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of Three Doses of Lurasidone HCl in Acutely Psychotic Patients with Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-002762-38 Sponsor Protocol Number: Clin-AGI001-001 Start Date*: 2005-04-13
    Sponsor Name:AGI Therapeutics Limited
    Full Title: A randomised, double-blind, placebo-controlled study of AGI 001 in the treatment of functional dyspepsia
    Medical condition: Functional (Non-ulcer) Dyspepsia
    Disease: Version SOC Term Classification Code Term Level
    7.0 10001394 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-001854-49 Sponsor Protocol Number: MSP-2017-5001 Start Date*: 2022-11-01
    Sponsor Name:Milestone Pharmaceuticals Inc.
    Full Title: Multi-Centre, Placebo-Controlled, Phase 2 Study of Etripamil Nasal Spray (NS) for the Reduction of Ventricular Rate in Patients with Atrial Fibrillation
    Medical condition: Treatment of Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004536-28 Sponsor Protocol Number: 1 Start Date*: 2021-11-15
    Sponsor Name:Uppsala University, Department of Women's and Children´s Health
    Full Title: Vaginal administration of selective estrogen receptor modulator (Tamoxifen) treatment to improve sexual function for women with breast cancer. A randomized, double-blinded, placebo controlled longi...
    Medical condition: Most troublesome vulvovaginal atrophy symptom
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002604-12 Sponsor Protocol Number: PSY-NIL-0010 Start Date*: 2022-02-09
    Sponsor Name:Medical University of Vienna
    Full Title: Unraveling the aesthetic mind in anhedonia, insights from pharmacological imaging of the human brain: A single-blind, randomized, placebo-controlled cross-over study
    Medical condition: Depression
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004554-42 Sponsor Protocol Number: TAMDMD Start Date*: Information not available in EudraCT
    Sponsor Name:University of Basel Children's Hospital, Division of Neuropediatrics
    Full Title: Tamoxifen in Duchenne muscular dystrophy: A multicenter, randomised, double-blind, placebo-controlled, phase 3 safety and efficacy 48-week trial Tamoxifen in Duchenne muscular dystrophy: A 48-week...
    Medical condition: Duchenne muscular dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Completed) ES (Prematurely Ended) NL (Prematurely Ended) BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-005738-41 Sponsor Protocol Number: CXXB750B12201 Start Date*: 2022-11-25
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A multi-center, randomized, double-blind, parallel-group, 20-week dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with resistant hypertension
    Medical condition: Resistant hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10081349 Resistant hypertension LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed) CZ (Completed) SK (Completed) IT (Completed) NL (Completed) DE (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004560-38 Sponsor Protocol Number: M04-729 Start Date*: 2014-11-12
    Sponsor Name:Abbott Deutschland GmbH & Co. KG
    Full Title: A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease.
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    17.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-002578-29 Sponsor Protocol Number: 2019-5787 Start Date*: 2020-01-21
    Sponsor Name:Radboudumc
    Full Title: Functional Improvement of non-infarcT relaTed coronary artery stenosis by Extensive LDL-C Reduction with a PCSK9 Antibody.
    Medical condition: Coronary artery disease (CAD) Optimal treatment approach for bystander lesions in non-infarct related arteries (non-IRA’s) has not been well established. Multiple RCT’s favor preventive PCI over ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003738-25 Sponsor Protocol Number: ESR-16-12160/UKE-DapEx-001 Start Date*: 2017-12-28
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: A 28-week, multi-center randomized, double-blind, placebo-controlled study to evaluate the potential of Dapagliflozin plus Exenatide in combination with high-dose intensive insulin therapy compared...
    Medical condition: Obese insulin-resistant patients with Type 2 Diabetes mellitus (T2DM) and inadequate glycemic control (HbA1c ≥ 8.0% and ≤ 11.0%)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000557-35 Sponsor Protocol Number: NW-1029/001/II/2003 Start Date*: 2005-06-09
    Sponsor Name:Newron Pharmaceuticals SpA
    Full Title: A phase II, multi centre, pilot, randomised, ascending dose, double -blind, placebo controlled, dose titration study to determine the safety, maximum tolerated dose and preliminary evidence of effi...
    Medical condition: Neuropathic pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-004953-24 Sponsor Protocol Number: 20041202 Start Date*: 2005-07-20
    Sponsor Name:Department of Anesthesiology, University Hospital Erlangen
    Full Title: A double-blind placebo-controlled two period crossover study of pregabalin and aprepitant in the electrical hyperalgesia model of central sensitisation in healthy volunteers
    Medical condition: The primary aim of the present study is therefore to investigate the effects of oral pregabalin and aprepitant on experimentally-induced central sensitization in the electrical hyperalgesia model, ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002761-63 Sponsor Protocol Number: HPV-301 Start Date*: 2018-04-16
    Sponsor Name:Inovio Pharmaceuticals, Inc.
    Full Title: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA™ 5PSP FOR THE TREATMENT OF HPV-16 AND/OR H...
    Medical condition: HPV-16 AND/OR HPV-18 RELATED HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (HSIL) OF THE CERVIX
    Disease: Version SOC Term Classification Code Term Level
    21.1 10022891 - Investigations 10064328 Human papilloma virus test positive PT
    21.1 100000004872 10066237 Cervical high grade squamous intraepithelial lesion LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) LT (Completed) FI (Completed) DE (Completed) CZ (Prematurely Ended) ES (Completed) PT (Completed) PL (Completed) SK (Completed) BE (Completed) NL (Ongoing) EE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002748-27 Sponsor Protocol Number: 0881A3-403 Start Date*: 2007-04-13
    Sponsor Name:Wyeth Pharmaceuticals France
    Full Title: A Multicentre, Double-Blind, Placebo-Controlled, Randomised Study of Etanercept in the Treatment of Adult Patients with Active, Severe and Advanced Axial Ankylosing Spondylitis
    Medical condition: Active, severe and advanced axial ankylosing spondylitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10048811 Bechterew's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) FR (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-016525-34 Sponsor Protocol Number: 28431754DIA3006 Start Date*: 2010-04-21
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 (Canagliflozin) Compared with...
    Medical condition: Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) BG (Completed) PT (Prematurely Ended) PL (Completed) SK (Completed) CZ (Completed) EE (Completed) SE (Completed) GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005122-31 Sponsor Protocol Number: CL2-16257-060 Start Date*: 2006-04-25
    Sponsor Name:Institut de Recherches Internationales (for France) [...]
    1. Institut de Recherches Internationales (for France)
    2. International Centre for Therapeutic Research (for Spain)
    Full Title: Evaluation of the effects on heart rate, haemodynamic parameters, safety and tolerability of 5 mg bolus of ivabradine followed by 8-hour infusion at the dose of 5 mg of ivabradine given after a per...
    Medical condition: Acute Myocardial Infarction
    Disease: Version SOC Term Classification Code Term Level
    3.3 10028596 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001550-27 Sponsor Protocol Number: CACZ885A2201 Start Date*: 2006-10-20
    Sponsor Name:Novartis Farmaceútica
    Full Title: Estudio aleatorizado, doble ciego, multicéntrico, controlado con placebo, de grupos paralelos, con búsqueda de dosis, de 12 semanas de duración para evaluar la eficacia, la seguridad, y la tolerabi...
    Medical condition: Artritis reumatoide activa
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) BE (Completed) FI (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 8  9  10  11  12  13  14  15  16  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Aug 02 09:42:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA